ADVA
2.6.2020 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Zenlayer is deploying its FSP 3000 technology to provide dynamic, highly available services to some of the world’s biggest gaming, cloud computing and social media companies. The solution will deliver flexible, ultra-low-latency connectivity, enabling the cloud service provider to address huge bandwidth needs as and when required. This is essential for Zenlayer’s customers that require highly resilient services with dynamic capacity. Built on the compact and scalable ADVA FSP 3000 platform , the new network will carry multiple services, including Ethernet, Fibre Channel and SONET/SDH. For maximum efficiency and elasticity, it also features ADVA’s QuadFlex™ line cards and OpenFabric™ cross-connect technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005062/en/
“With this deployment, we’re injecting new levels of flexibility and reliability into our infrastructure. ADVA’s technology offers a major boost to our customers who are delivering more and more data-intensive real-time services to their end users. It opens the door to the next generation of teleconferencing, streaming and online gaming technologies,” said Alex Wang, network architect and product manager, Zenlayer. “Our new solution is extremely efficient in terms of footprint and power consumption. It’s also a future-proof investment ready to scale even further in years to come. Another key component in the success of the project was our close working relationship with ADVA’s engineers. They made sure the whole process was seamless and speedy from network design to shipment and implementation.”
Zenlayer’s new transport network includes some of ADVA’s most innovative technology. Specifically designed for scale and bandwidth optimization, the ADVA FSP 3000 platform ensures that the infrastructure meets the most stringent density and energy demands. Using ADVA FSP 3000 QuadFlex™ technology, the solution delivers outstanding spectral efficiency. The new network also features the ADVA FSP 3000 OpenFabric™ , an OTN cross-connect that creates a distributed architecture, empowering Zenlayer to simply and efficiently adjust bandwidth and turn up new services in an instant. What’s more, for Zenlayer customers such as public cloud and global gaming companies, the solution’s low-latency, high-availability performance will translate directly into end-user satisfaction.
“This deployment will benefit a great number of enterprises operating in Taiwan and Singapore. With the ability to flexibly and efficiently transport multi-traffic services at speeds up to 200Gbit/s, Zenlayer’s telecom, cloud service and gaming customers can enhance the experience of their end users and gain a vital competitive edge,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Zenlayer has a clear vision of what its customers expect and a bold strategy for delivering it. By harnessing our technology and the expertise of our engineers, Zenlayer has created a network ready to adapt to evolving demands and able to expand further in years to come.”
“Our open FSP 3000 technology is the ultimate response to ever-increasing data requirements. It gives Zenlayer the tools it needs to grow its network and develop its edge cloud services in a cost-efficient and highly sustainable way,” said Rocky Weicong Zhou, director, global business development, ADVA. “Combined with our QuadFlex™ and OpenFabric™ technologies, our FSP 3000 platform provides superb levels of capacity and agility. It enables Zenlayer to respond flexibly to huge increases in traffic volume while at the same time making savings on energy use and rack space. With a highly flexible and efficient transport system, Zenlayer can give its enterprise customers world-class connectivity to markets across the globe.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005062/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
